Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib
{{output}}
Accumulating evidence suggests local consolidative therapy may delay resistance and benefit metastatic NSCLC patients with oligo-residual disease (ORD) after effective systemic therapy. However, the incidence and clinical features of ORD in Alectinib-treated m... ...
